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Abstract
Rifampin is a pleiotropic inducer of multiple drug metabolizing enzymes and trans-
porters. This work utilized a global approach to evaluate rifampin effects on conju-
gating enzyme gene expression with relevance to human xeno- and endo-biotic
metabolism. Primary human hepatocytes from 7 subjects were treated with rifampin
(10 lmol/L, 24 hours). Standard methods for RNA-seq library construction, EZBead
preparation, and NextGen sequencing were used to measure UDP-glucuronosyl
transferase UGT, sulfonyltransferase SULT, N acetyltransferase NAT, and glu-
tathione-S-transferase GST mRNA expression compared to vehicle control (0.01%
MeOH). Rifampin-induced (>1.25-fold) mRNA expression of 13 clinically important
phase II drug metabolizing genes and repressed (>1.25-fold) the expression of 3
genes (P < .05). Rifampin-induced miRNA expression changes correlated with mRNA
changes and miRNAs were identified that may modulate conjugating enzyme
expression. NAT2 gene expression was most strongly repressed (1.3-fold) by rifam-
pin while UGT1A4 and UGT1A1 genes were most strongly induced (7.9- and 4.8-
fold, respectively). Physiologically based pharmacokinetic modeling (PBPK) was used
to simulate the clinical consequences of rifampin induction of CYP3A4- and
UGT1A4-mediated midazolam metabolism. Simulations evaluating isolated UGT1A4
induction predicted increased midazolam N-glucuronide exposure (~4-fold) with min-
imal reductions in parent midazolam exposure (~10%). Simulations accounting for
simultaneous induction of both CYP3A4 and UGT1A4 predicted a ~10-fold decrease
in parent midazolam exposure with only a ~2-fold decrease in midazolam N-glucuro-
nide metabolite exposure. These data reveal differential effects of rifampin on the
human conjugating enzyme transcriptome and potential associations with miRNAs
that form the basis for future mechanistic studies to elucidate the interplay of con-
jugating enzyme regulatory elements.
Abbreviations: CYP, cytochrome P450; DMSO, dimethyl sulfoxide; GEO, Gene Expression Omnibus; GST, glutathione-S-transferase; miRNA, microRNA; NAPQI, N-acetyl-p-benzoquinone
imine; NAT, N acetyltransferase; PBPK, physiologically based pharmacokinetic; PXR, pregnane X receptor; SULT, sulfonyltransferase; TPMT, thiopurine S-methyltransferase; UGT, UDP-
glucuronosyl transferase.
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1 | INTRODUCTION
Rifampin induction of cytochrome P450 is an extensively studied
drug–drug interaction mechanism resulting in a substantial list of
clinically important interactions that can lead to reduced drug effi-
cacy or increased toxicity.1,2 In contrast, relatively less is known
about rifampin induction of human conjugating enzymes including
uridine diphosphate glucuronosyltransferases (UGTs), sulfotrans-
ferases (SULTs), N-acetyltransferases (NATs), thiopurine S-methyl-
transferase (TPMT) and glutathione S-transferases (GSTs).3 Rifampin
is widely recognized as a pleiotropic but specific inducer of drug
metabolizing enzymes and transporters with effects mediated mainly
through activation of pregnane X receptor (PXR).4 The genes regu-
lated by PXR include those encoding for human conjugating enzyme
families (UGTs, SULTs, NATs, and GSTs). Previous studies demon-
strated rifampin induction of miRNAs and association with repres-
sion of P450 genes, suggesting the possibility of additional
epigenetic mechanisms underlying rifampin drug–drug interactions.5,6
Epigenetic modulation of conjugating enzymes by miRNAs has also
been demonstrated.7-10 MiRNAs generally are thought to negatively
regulate gene expression and reduce downstream protein translation
via imperfect complementary binding with the 30-untranslated
region. However, relatively little is known about the combined
effects of rifampin-induced changes in hepatic miRNA expression on
the downstream expression of conjugating enzymes.
The UGT superfamily of conjugating enzymes contains 5 subfam-
ilies (UGT1, UGT2A, UGT2B, UGT3, and UGT8). Three of these sub-
families (UGT1, UGT2A, and UGT2B) prominently contribute to the
metabolism of drugs, dietary substances, toxicants, and endogenous
substrates with broad and overlapping substrate specificities. These
3 subfamilies are encoded by 10 genes to generate 19 isoforms in
humans.11 The UGT1A family shares a single chromosomal locus
(band 2q37) with the 9 different functional isoforms being generated
via splicing of shared exons 2-5 to an isoform-specific exon 1. Simi-
larly, the UGT2A subfamily members share exons 2-6 with an iso-
form-specific exon 1. Conversely, the UGT2B family is composed of
7 functional enzymes encoded by individual genes. Each UGT pos-
sesses a unique 50-upstream promoter region that controls its tran-
scription as well as more distant enhancer regions containing
transcription factor-binding sites that further control constitutive and
inducible UGT expression. A wide variety of tissue-specific and
ligand-activated transcription factors modulate the induction of UGT
genes including PXR.12 In addition, epigenetic UGT regulation by
miRNAs has recently been identified as another factor that modu-
lates UGT expression and response to environmental exposures.7-
10,13,14 Taken together, evaluating the influence of rifampin on UGT
mRNA expression and association with miRNA changes may help to
unravel the complex regulatory network governing UGT expression
and activity.
The cytosolic SULT family of enzymes contribute to the metabo-
lism of several exogenous and endogenous substrates, including the
clinically used drugs acetaminophen, minoxidil, and ethinyl estradiol.
The SULT family is comprised of 13 members within 3 families
(SULT1, SULT2, and SULT4). SULT activity varies widely among indi-
viduals due in part to genetic polymorphisms and susceptibility to
induction via nuclear receptor activation.15-17 For women taking
ethinyl estradiol, rifampin induction of SULTs may cause therapeutic
failure of the oral contraceptive drug.18 Despite the clinical impor-
tance of SULT-mediated xenobiotic metabolism, data describing
mechanisms regulating SULT induction are rather sparse.
NATs, another family of conjugating enzymes, contribute to
human xenobiotic and endogenous substrate metabolism. Two NATs,
NAT1 and NAT2, are thought to be of primary importance to drug
metabolism. Polymorphisms exist in both NAT1 and NAT2 genes
with well-established functional consequences in phenotypic slow
acetylators. For example, slow acetylators are more susceptible to
drug-induced toxicities from hydralazine and isoniazid. Isoniazid and
rifampin are also commonly coadministered for the treatment of
latent tuberculosis, raising the potential for drug–drug interactions.
Slow acetylators are also more prone to developing certain can-
cers.19 As a result, NAT modulation via small molecules and miRNAs
has become a target of drug and biomarker development.20,21 Con-
sidered together, understanding the rifampin-induced changes in
NAT expression and associated miRNAs may be of therapeutic and
diagnostic value.
TPMT is the primary enzyme responsible for human metabolism
of thiopurine drugs including azathioprine, thioguanine, and 6-mer-
captopurine. Genetic polymorphisms in TMPT can result in reduced
enzyme activity leading to increased drug concentration and toxici-
ties in certain patients. As a result, pharmacogenetics screening for
TPMT deficiency is recommended prior to initiating thiopurine drug
therapy. A previous report demonstrated no change in TPMT mRNA
expression in human hepatocytes treated with rifampin3 but the
potential influence of miRNAs has not been previously explored.
Human GSTs are a family of cytosolic enzymes that catalyze the
transfer of the sulfhydryl group of glutathione to a large variety of
electrophiles, including drug molecules such as busulfan and ethacry-
nic acid and reactive CYP450 metabolites such as N-acetyl-p-benzo-
quinone imine (NAPQI). GST induction by drug molecules and
dietary flavonoids has been previously reported22,23 but the poten-
tial relationship with miRNA expression changes has not been evalu-
ated.
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The first aim of this report was to describe the effects of rifam-
pin treatment on the regulation of hepatic conjugating enzyme
mRNA expression and the relationships with regulation of miRNA
expression in primary human hepatocytes. The second aim was to
further assess the impact of rifampin modulation of UGT mRNA
expression in human renal proximal tubule cells to evaluate the
potential for tissue-specific changes in enzyme regulation. Finally,
based upon the in vitro and in silico study results, rifampin induction
of UGT1A4-mediated metabolism was selected for further evaluation
via physiologically based pharmacokinetic (PBPK) modeling and simu-
lation. The overarching goal of this work was to globally evaluate
rifampin’s effects on conjugating enzyme gene expression with rele-
vance to human xeno- and endobiotic metabolism.
2 | MATERIALS AND METHODS
2.1 | Primary human hepatocytes and drug
treatments
This study evaluated mRNA and miRNA expression data collected in
a previously published human hepatocyte experiment.5,6 In brief,
freshly isolated human hepatocytes from 7 different donors were
obtained from CellzDirect (Durham, NC) and were plated on 12-well
collagen-coated plates cultured in Williams’ E medium without phe-
nol red containing Primary Hepatocyte Maintenance Supplements
(Life Technologies Corporation, Carlsbad, CA). Cultures from each
donor were considered biological replicates (n = 7). All studies were
performed within 72 and 120 hours following the time of hepato-
cyte isolation. Hepatocytes were treated with rifampin (10 lmol/L)
or corresponding vehicle control (0.1% methanol) for 24 hours. The
commercially obtained human hepatocytes were deidentified and
specific demographic and/or clinical information were not available
from the supplier.
2.2 | MicroRNA expression profiling and
bioinformatics analysis
Total RNA, including small RNAs, was isolated from the human hepa-
tocytes following treatment, using the miRNeasy kit (Qiagen, Valen-
cia, CA) with optional on-column DNase treatment included in the
purification. Expression of 754 miRNAs was measured using the
Taqman OpenArray Human miRNA Panel with an NT Cycler (Applied
Biosystems, Foster City, CA). Each subject’s RNA was analyzed on 2
different OpenArrays to yield technical duplicates. Threshold cycles
were set manually based on visual inspection of the real-time ampli-
fication curves of each individual miRNA. Final analysis of technical
duplicates was completed within a single project to ensure that the
same adjusted threshold was applied to each pair. CT values were
transformed to positive values (40-CT) to ensure appropriate direc-
tionality of effect for the correlation analyses with RNA-seq data.
The remaining miRNA bioinformatics analyses mirrored that
described in a previous analysis of this data set for evaluation of
transport protein changes.5
2.3 | Bioinformatic analysis of the RNA-seq data
RNA-seq library construction, EZBead preparation, and NextGen
sequencing were performed using standard methods as described
previously6 and used to measure UGT, SULT, NAT, TPMT, and
GST mRNAs and compared to vehicle control (0.1% methanol).
UGT1A genes were identified and quantified by unique exons 1
as exons 2-5 are shared across this gene subfamily. The RNA-Seq
data analysis included quality assessment and sequence alignment
prior to differential gene expression analysis as described previ-
ously.6 In brief, SOLiD Instrument Control Software and Experi-
ment Tracking Software were used for read quality recalibration.
Each sequence was scanned for low-quality reads and any read
length of less than 35 bases was discarded to effectively eliminate
low-quality reads while retaining high-quality regions. BFAST was
used as the primary sequence alignment algorithm employing a
TopHat-like strategy to align sequencing reads that crossed splic-
ing junctions. Sequence reads were aligned to a filtering index to
exclude sequences that were not of interest (eg, repeats and ribo-
somal RNA). Analyses were restricted to uniquely aligned
sequences with 2 or less mismatches. Differentially expressed
genes were identified using edgeR following exclusion of genes
with less than 1 read per million mappable reads in more than
half of samples. A generalized linear model considering the effects
of individual donors as a random effect was used to identify gene
expression levels directly affected by rifampin treatment. The P-
values were calculated for each gene and Benjaminin and Hoch-
berg’s algorithm was used to control the false discovery rate. Data
reported in the primary tables and figures only for genes up- or
downregulated >1.25-fold by rifampin and P < .05. Clustering of
mRNA expression changes and hepatocyte donors depicted in
dendrograms were determined, using Euclidian distances and the
complete linkage clustering method. Data visualization and hierar-
chical cluster analysis were performed with R software (build
3.2.3) and R Studio (v. 0.99.491), using the gplots and ggplots2
packages.
2.4 | Rifampin treatment of human renal proximal
tubule cells
Immortalized normal human proximal tubular kidney (NHPTK)
cells24 were maintained in REGM media (Lonza, Basel, Switzerland)
supplemented with 10% fetal bovine serum (Hyclone, GE Health-
care Bio-Sciences, Pittsburgh, PA, USA) to maintain appropriate
renal phenotype. NHPTK cells were maintained at 37°C in 95%
humidified atmosphere (5% CO2). Studies were performed on cells
in passages 6-9 (corresponding to passage 3-6 post-immortalization)
with individual passages considered a biological replicate (n = 4).
NHPTK cells were treated with rifampin (10 lmol/L) or vehicle
control (0.01% methanol) for 24 hours. Following treatment, ~1 mil-
lion cells were washed in ice-cold PBS, recovered via centrifuga-
tion, and the resultant pellet stored at 80°C pending RNA
isolation.
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2.5 | Quantitative real-time PCR of renal cells
Total RNA was extracted, using the miRNeasy Plus Mini Kit (Qia-
gen, Hilden, Germany) manufacturer protocol. UGT1A1, 1A6, 1A9,
and 2B7, expression levels were determined via qRT-PCR using
GAPDH as an endogenous control. RNA quantification and quality
were assessed, using optical spectrometry ratios (260/280 and
260/230 nm); mRNA was reverse transcribed to cDNA using the
iScript Reverse Transcription Kit (Bio-Rad, Hercules, CA) and
diluted to obtain 25 ng/mL final cDNA concentration. Here, qRT-
PCR was performed on an Applied Biosystems Quantum Studio
Viia 7 system with iTaq Universal SYBR Green (Bio-Rad) and cus-
tom made primers (Life Technologies). The thermocycler parame-
ters were 95°C for 30 seconds, then 40 cycles consisting of 95°C
for 15 seconds followed by an annealing temperature for 30 sec-
onds. Primer sequences and annealing temperatures are provided
in Table S1. The delta–-delta CT method was applied to determine
the relative expression of each gene for rifampin and vehicle-trea-
ted cells as previously described.5 The fold change in gene expres-
sion is represented as the mean  SEM of the biological
replicates (n = 4).
2.6 | ChIP-seq PXR-binding site in silico analysis
The conjugating enzyme genes in this study were evaluated in silico
for PXR-binding sites using a publically available ChIP-Seq database
generated using HepG2 cells treated with vehicle (dimethyl sulfoxide,
DMSO) or rifampin.25 The in silico ChIP-Seq testing was conducted
as described previously.5 Promoter regions were specified as 2 kb
based upon the coordinates of each transcription start site.
2.7 | Accession numbers
Raw RNA-seq data were made publicly available through the
National Center for Biotechnology Information Gene Expression
Omnibus (GEO) database and can be accessed, using GEO series
accession number GSE799933 (http://www.ncbi.nlm.nih.gov/ge
o/query/acc.cgi?acc=GSE79933). OpenArray miRNA data were made
publically available through the Indiana University Center for Com-
putational Biology and Bioinformatics and can be accessed at
http://compbio.iupui.edu/group/6/pages/rifampin.
2.8 | Physiologically based modeling and simulation
The potential clinical impact of rifampin induction of UGT1A4-
mediated midazolam N-glucuronidation was evaluated via PBPK
modeling and simulation, using the SimCYP population-based simula-
tor (version 15.1; SimCYP Limited, Sheffield, UK). The midazolam
SimCYP library file was modified to describe the clinically observed
disposition of the UGT1A4-mediated N-glucuronide metabolite of
midazolam. The midazolam N-glucuronide compound file was linked
to the parent compound and designated as “Primary Metabolite 1”
within the software. Midazolam N-glucuronide model development
was accomplished, using clinical data previously acquired during the
control phase of a healthy volunteer (n = 12) herbal product–drug
interaction study.26 SimCYP model parameters are available in
Table S2. Simulated pharmacokinetic outcomes within 30% of
observed endpoints were deemed sufficiently accurate to proceed
with interaction simulations. Drug–drug interactions resulting from
coadministration of rifampin (600 mg/day orally for 3 days) with
midazolam (5 mg orally on day 3) were simulated in 10 virtual trials
of 10 healthy volunteers (ages 20–50 years, 50:50 male:female). Ini-
tial simulations evaluated only the impact of a fivefold increase in
the hepatic UGT1A4 mediated metabolism of midazolam achieved
semimechanistically using the “UGT scalar” option within SimCYP.
Subsequent simulations incorporated the impact of a simultaneous
fivefold increase in UGT1A4 metabolism along with mechanistic
description of rifampin-induced changes in CYP3A4 activity. The
multiple dose rifampicin library file within the SimCYP model was
used as provided to describe rifampin induction of CYP3A. The only
exception was that the maximal fold induction (Indmax) for CYP3A4/
5 was set to 22.7, the mean value observed in the current hepato-
cyte experiments. The directly observed fold mRNA change was uti-
lized based upon the assertion that appropriate use of higher Indmax
values improves model prediction accuracy of drug–drug interactions
mediated via CYP3A4 induction.27
3 | RESULTS
3.1 | Rifampin regulation of hepatocyte drug
metabolizing gene expression
The effects of rifampin on the hepatocyte expression of 53 phase II
drug metabolizing enzyme enzymes was evaluated by differential
mRNA expression. The effects of rifampin on selected enzymes
(greater than 1.25-fold change in mRNA expression and P < .05) are
outlined in Table 1. Rifampin treatment significantly induced the
expression of 13 genes and repressed the expression 3 genes.
UGT1A5 expression was induced by ~twofold in agreement with
previous reports of rifampin induction (3.5-fold)28 in human hepato-
cytes. UGT family mRNA expression was isoform dependent and
induced or not changed in response to rifampin treatment (Figure 1).
However, multiple members of the UGT1A enzyme family consis-
tently demonstrated induction in response to rifampin treatment
across all 7 hepatocyte donors (Figure S1). Here, mRNA expression
of 3 NAT isoforms appeared to be repressed in response to rifampin
treatment with the remaining isoforms largely unchanged (Figure 1).
SULT2A1 mRNA expression was induced while SULT1B1 and 1E1
expression was repressed (Figure 1). SULT1E1 and SULT1B1 mRNA
expression were repressed to a similar extent, a result consistent
with reported coregulation of these 2 genes.29 Changes in GST
mRNA expression were modest with mixed induction and repression
observed (Figure 1). Consistent with previous report,3 TPMT mRNA
expression was unchanged by rifampin treatment. Observed changes
in mRNA expression were largely consistent across biological repli-
cates with the exception of strong induction of UGT2A1 and GSTO2
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observed only in hepatocytes from donor 5 (Figure S1). UGT1A4
and UGT1A1 were most strongly induced suggesting the possibility
of clinically relevant drug–drug interactions resulting from concomi-
tant rifampin administration with drug substrates of these enzymes
and prompting further evaluation via physiologically based modeling
and simulation.
3.2 | Conjugating enzymes and CYP450 isoforms
appear to be coordinately regulated
Coordinate regulation of CYPs, UGTs, and transporters has been pro-
posed as a defense mechanism providing protection against various
chemical stressors.30 Correlation analysis suggests that several conju-
gating enzymes are coordinately regulated in response to rifampin
treatment. As expected, multiple UGT genes displayed strong positive
correlations in rifampin-induced expression changes (Table 2).
UGT1A4 and UGT2B15 expression changes positively correlated with
changes in UGT2B4 expression. Our results are in agreement with the
literature reported protein pairs of UGT1A4/2B4 (rs=.71, P < .0001,
n = 82) and UGT2B4/2B15 (rs = .63, P < .0001, n = 83) from a recent
meta-analysis.31 Interestingly, expression changes of multiple GST
enzymes were negatively correlated with changes in UGT1A and 2B
expression (Table 2). Changes in UGT1A1 expression correlated posi-
tively with changes in CYP3A7 and CYP2B6 expression while UGT1A5
expression negatively correlated with changes in CYP3A5 and CYP2E1
(Table 3). Interestingly, significant correlations were not observed
between the major CYPs (eg, CYP1A2, 2C8, 2C9, and 3A4/5) and
UGTs (UGT1A1, 1A3, 1A4, 1A9, 2B7). These data provide further evi-
dence for coordinate regulation of drug metabolizing enzymes in
response to rifampin treatment.
3.3 | Changes in miRNA and conjugating enzyme
mRNA expression are highly correlated
Correlation analyses between changes in miRNA expression and
mRNA changes were performed to identify miRNAs that may regu-
late conjugating enzyme expression. Typically, miRNAs are expected
to downregulate target gene expression which would result in a neg-
ative correlation in this analysis. However, changes in miRNA
expression were both positively and negatively correlated with con-
jugating enzyme mRNA expression (Table 4), similar to a previous
report of miRNA and CYP450 correlations.6 Five of the miRNA/RNA
pairs identified, using correlation analysis were also predicted via
TargetScan (Release 7.1).32 hsa-miR-200b was negatively correlated
with SULT1A1, SULT1A2, and NAT2 (Table 4); consistent with
downregulation of those genes by the miRNA. Rifampin-induced
expression of hsa-miR-200b may underlie the observed repression of
NAT2 (Figure 1B, Table 1). The hsa-miR-766 was previously pre-
dicted in silico to target the HNF4a nuclear receptor6 which may
explain the observed correlations with changes in UGT1A3,
UGT2B4, UGT2B15, GSTO1, and GSTT1 mRNA expression. The vast
miRNA and transcription factor network that controls the expression
of the various conjugating enzymes likely underlies the observed
positive and negative correlations.
TABLE 1 Effect of rifampin on the expression of selected conjugative drug metabolizing enzymes in human hepatocytes
Gene Fold changea P-value FDR Examples of substrates
Upregulated
UGT1A4 4.93 9.85 9 10113 1.14 9 10109 Amitriptyline, endoxifen, imipramine, midazolam
UGT1A1 3.19 2.82 9 1070 1.64 9 1067 Acetaminophen, bilirubin, SN-38, raltegravir
SULT2A1 2.44 2.78 9 1044 9.59 9 1042 Androgens, dehydroepiandrosterone
UGT1A3 2.40 2.76 9 1030 7.06 9 1028 Ezetimibe, naproxen, quercetin
UGT1A5 2.07 8.79 9 1017 1.15 9 1014 1-hydroxypyrene, 4-methylumbelliferone, scopoletin
GSTA1 1.92 1.51 9 1021 2.72 9 1019 Busulfan, chlorambucil, thiotepa, androstene-3,17-dione
UGT2B4 1.89 3.54 9 1024 7.30 9 1022 Lorazepam, bile acids, carvedilol
GSTA2 1.87 3.80 9 1014 3.57 9 1012 Busulfan, dibenzopyrene diolepoxide
UGT2B11 1.76 1.27 9 103 1.32 9 102 12-hydroxyeicosatetraenoic acid (HETE), 15-HETE
GSTM2 1.69 6.63 9 103 4.71 9 102 1-chloro-2,4-dinitrobenzene
GSTM1 1.68 1.65 9 107 6.08 9 106 Artemisinin
SULT1A2 1.61 2.16 9 102 1.07 9 101 Minoxidil, b-napthol
UGT2B15 1.28 1.70 9 104 2.64 9 103 Acetaminophen, (S)-oxazepam, tolcapone
Downregulated
SULT1B1 0.55 2.72 9 1018 4.09 9 1016 1-napthol, 4-nitrophenol, tri-iodothyronine
SULT1E1 0.57 9.87 9 1010 5.30 9 108 Estrogen, naringenin, 4-hydroxytamoxifen, curcumin
NAT2 0.75 5.06 9 105 9.41 9 104 Dapsone, sulfasalazine, isoniazid
FDR, false discovery rate.
aRifampin/control; reported only for genes up- or down-regulated >1.25-fold and P < 0.05.
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3.4 | Rifampin modulation of UGT gene expression
is cell line specific and appears to be largely PXR
dependent
Rifampin treatment did not significantly alter the expression of
UGT1A1, 1A6, 1A9, or 2B7 in NHPTK cells. The observed fold changes
ranged from 0.95 to 1.04, consistent with a previously reported lack of
PXR expression in this cell line.5 In Silico ChIP-Seq analysis of rifampin-
treated HepG2 cells found PXR peaks within the promoter regions of 4
clinically relevant conjugating enzyme genes: UGT1A4, UGT1A6,
SULT2A1, and GSTO1. ChiP-Seq analysis was in agreement with the
RNA-seq results demonstrating increased gene expression of UGT1A4
and SULT2A1, suggesting a PXR-mediated induction process.
3.5 | Physiologically based modeling and simulation
suggests that UGT induction contributes to observed
rifampin–drug interactions with dual CYP3A/UGT
substrates
Simulated midazolam and midazolam N-glucuronide concentration-
time profiles closely approximated clinically observed disposition and
pharmacokinetic outcomes (Figure 2A and B, Table 5). Simulations
evaluating the impact of rifampin-induced UGT1A4 metabolism in iso-
lation predicted markedly increased midazolam N-glucuronide expo-
sure (~fourfold) with minimal reductions in parent midazolam exposure
(~10%), consistent with midazolam clearance-mediated primarily by
CYP3A4 (Figure 2C and D, Table 5). CYP3A4 induction only was pre-
dicted to reduce systemic midazolam exposure by nearly 10-fold, in
concordance with previous clinical and PBPK model-predicted reports
of hepatic CYP3A4 induction.27 Midazolam N-glucuronide exposure
was also predicted to be substantially reduced by rifampin, reflective
of drastically reduced parent midazolam exposure leading to reduced
substrate availability for UGT1A4-mediated N-glucuronidation. Simul-
taneous evaluation of UGT1A4 and CYP3A4 induction predicted >10-
fold mean reduction in plasma midazolam exposure but only ~2-fold
reduction in midazolam N-glucuronide exposure, suggesting that the
effects of limited substrate availability are partially overcome by simul-
taneous UGT1A4 induction.
4 | DISCUSSION
Successful mitigation of CYP450 metabolic liabilities during drug
development has increased the importance of non-CYP450 enzyme
F IGURE 1 Individual changes in mRNA expression grouped by gene family; (A) UDP-glucuronsyltransferases (UGTs), (B)
N-acetyltransferases (NATs), (C) sulfotransferases (SULTs), and (D) glutathione-S-transferases determined via RNA-seq. Dots denote individual
observed data points for each biological replicate (n = 7). Boxes denote observed median and interquartile range (IQR), whereas whiskers
depict 1.5 times the IQR.
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contributions to drug metabolism. However, evaluation of non-
CYP450 mediated xenobiotic metabolism continues to pose
research, development, and regulatory challenges.33 Standardized
in vitro models to assess conjugating enzyme contributions to xeno-
biotic clearance and approaches to predict clinical consequences are
evolving. As a result, mechanistic understanding of these metabolic
pathways and reports of the effects of modulators of conjugating
enzyme activity are relatively limited compared to the CYP450 sys-
tem. This report outlines the effects of rifampin induction of conju-
gating enzyme expression and potential modulation via induced
miRNA expression. These data: (1) show that several clinically rele-
vant conjugating enzymes are inducible by rifampin; (2) support the
association of rifampin-induced miRNA modulation of conjugating
enzyme expression; (3) indicate that UGT induction is cell-line
dependent; and (4) suggest the potential clinical relevance of UGT
induction by rifampin.
Of the non-CYP450 enzymes that contribute to xenobiotic meta-
bolism, UGTs are the most important in terms of abundance in hep-
atic and extrahepatic tissues as well as in the wide range of
xenobiotics including many drugs and endobiotics they metabolize.
Drug–drug interactions mediated via UGT induction are inherently
difficult to predict from in vitro data.33 LC-MS/MS approaches to
directly quantify UGT protein content within in vitro systems and
human tissues34-40 have enhanced in vitro–-in vivo extrapolation of
UGT mediated metabolism. Future studies of UGT induction could
leverage combinatorial approaches (eg, RNAseq and LC-MS/MS) to
provide complementary information. UGT1A1 has been previously
demonstrated to be induced by treatment with dietary polyphenols
including resveratrol, curcumin, and chrysin in Caco-2 cells,41,42
human hepatocytes,43 and PXR reporter assays.44 However, rapid
metabolism and minimal systemic exposure of many dietary polyphe-
nols may limit their ability to induce hepatic UGTs in vivo.45 In con-
trast, rifampin and other prototypic drug inducers are expected to
produce systemic exposure sufficient to result in clinically relevant
enzyme induction.46 Rifampin induction of UGT1A5 has been
reported previously in human hepatocytes. Detection of hepatic
UGT1A5 protein in human livers not exposed to rifampin is limited,
suggesting that hepatic UGT1A5 is expressed only in response to
xenobiotic exposure.
In agreement with previous report, SULT2A1 mRNA expression
was induced while SULT1A1 was not altered by treatment with
rifampin.47 Consistent repression of SULT1E1 and SULT1B1 gene
expression was not expected to result from rifampin treatment par-
ticularly when considering previous reports of the interaction
between rifampin and ethinyl estradiol.18 However, repression of
SULT1E1 and SULT1B1 may result from the complex interplay of
multiple rifampin-induced transcription factors, similar to the mecha-
nism described for rifampin repression of CYP7A1 expression.48 This
TABLE 2 Correlations of rifampin-induced changes in the mRNA
expression among the conjugating enzymes
Gene 1 Gene 2 Correlation coefficienta P-value
Positive correlation
GSTA1 SULT2A1 .96 .003
UGT1A3 UGT2B4 .96 .003
GSTM2 GSTM4 .93 .007
SULT1B1 UGT1A5 .89 .012
UGT2B15 UGT2B4 .89 .012
SULT1E1 UGT2B17 .86 .024
SULT2A1 UGT2B15 .86 .024
UGT1A3 UGT2B15 .86 .024
UGT1A3 UGT2B17 .86 .024
GSTA1 UGT2B15 .82 .034
UGT1A3 UGT1A5 .82 .034
UGT1A4 UGT2B4 .82 .034
UGT1A5 UGT2B17 .82 .034
UGT1A9 UGT2B11 .82 .034
GSTA1 SULT1A2 .79 .048
NAT2 SULT1A1 .79 .048
Negative correlation
GSTT1 UGT2B4 .96 .003
GSTT1 UGT1A3 .93 .007
GSTA4 UGT1A1 .86 .024
GSTM1 UGT2B11 .86 .024
GSTA1 GSTT1 .82 .034
GSTO1 UGT1A4 .82 .034
GSTT1 UGT2B15 .82 .034
GSTA1 GSTM2 .79 .048
GSTZ1 UGT1A4 .79 .048
aSpearman correlation as assumption of normal distribution could not be
made. Data recovered via RNA-seq.
Only significant correlations (P < 0.05 by Spearman correlation) are
reported for those conjugating enzymes modulated by rifampin (>1.25
mean fold change, FDR <0.05).
TABLE 3 CYP450 genes correlated with clinically relevant
conjugating enzyme genes
Gene 1 Gene 2 Correlation coefficienta P-value
Positive correlation
UGT1A1 CYP3A7 .96 .003
UGT1A5 CYP1B1 .86 .024
UGT1A9 CYP1A1 .86 .024
UGT2B4 CYP2D6 .86 .024
SULT1B1 CYP1B1 .82 .034
NAT2 CYP2J2 .82 .034
UGT1A1 CYP2B6 .79 .048
Negative correlation
GSTM1 CYP4F2 .86 .024
UGT1A5 CYP3A5 .79 .048
UGT1A5 CYP2E1 .79 .048
aSpearman correlation as assumption of normal distribution could not be
made. Data recovered via RNA-seq. Only significant correlations reported
(P < 0.05 by Spearman correlation).
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may suggest that rifampin induces regulatory elements that act to
suppress SULT1E1 and SULT1B1 mRNA expression, such as miRNAs
or transcription repressors, or mechanisms other than rifampin acti-
vation of PXR may underlie the observed changes.
Expression of NAT2 mRNA was the most strongly repressed
gene by treatment with rifampin. The mechanistic basis for this
observation remains to be elucidated. Nevertheless, this novel
in vitro observation may provide an alternate explanation for the
clinically observed increase in hepatotoxicity that results from coad-
ministration of rifampin with the NAT2 substrate isoniazid.49,50 The
mechanistic underpinnings of this drug–drug interaction have been
the source of some debate as it does not appear to be related
directly to induction of CYP450-mediated reactive metabolite con-
centrations in humans or PXR-humanized mice.51,52 Mouse models
suggest that human PXR modulates hepatotoxicity associated with
rifampin and isoniazid via increased accumulation of an endogenous
hepatotoxin.51 However, human NAT2 genetic polymorphisms that
result in a slow acetylator phenotype have been strongly associated
with increased risk of isoniazid hepatotoxicity. It then leads that per-
haps rifampin down-regulation of NAT2 is creating a drug-induced
slow acetylator phenotype that leads to increased risk of isoniazid
hepatotoxicity when administered with rifampin. Rifampin-induced
formation of hydrazine from isoniazid has been posited to underlie
increased hydrazine plasma levels observed in patients taking rifam-
pin and isoniazid as compared to those taking isoniazid alone.53
Alternatively, repressed NAT2 activity leading to impaired hydrazine
elimination, or a combination of both increased formation and
reduced elimination, may explain the apparent increase in hydrazine
exposure caused by rifampin. Further reduction in limited NAT2
activity by rifampin could potentially explain reports of increased
incidence of hepatotoxicity when slow acetylators take isoniazid and
rifampin.54
The alpha-class GSTs catalyze the GSH-dependent detoxification
of several alkylating chemotherapy agents and numerous environ-
mental pollutants.55 GST induction has also been suggested, using
high-sensitivity real-time PCR3 and likely represents another defense
mechanism against xenobiotic exposure. The observed changes in
GST expression measured via RNAseq are in alignment with previous
reports using alternate quantification approaches.
TABLE 4 Conjugating enzyme-miRNA pair correlations consistent
with miRNA modulation of conjugating enzyme gene expression in







hsa-miR-638 GSTT1 .99 .0004
hsa-miR-766 GSTT1 .96 .003
hsa-miR-92a UGT1A9 .93 .007




hsa-miR-92a UGT2B11 .89 .012
hsa-miR-92a UGT2B7 .89 .012
hsa-miR-30dc GSTM4b .86 .024
hsa-miR-660 GSTA4 .86 .024
hsa-miR-320 UGT3A1b .86 .024
hsa-miR-616 SULT1A1 .86 .024
hsa-miR-200a GSTZ1 .86 .024
hsa-miR-200a GSTO1 .86 .024




hsa-miR-92a TPMTb .82 .034
hsa-miR-320 SULT1A1 .82 .034
HSA-MIR-1180 NAT15 .82 .034
hsa-miR-361 NAT1 .79 .048
hsa-miR-92a GSTCD .79 .048
hsa-miR-30dc GSTM2 .79 .048
hsa-miR-660 GSTT1 .79 .048
hsa-miR-21 GSTT1 .79 .048
Negative correlation
hsa-miR-766 UGT1A3 .96 .003
hsa-miR-148bc GSTO1 .96 .003
hsa-miR-200bc SULT1A1 .9 .006
hsa-miR-766 UGT2B4b .93 .007
hsa-miR-18a UGT2B17 .89 .012
hsa-miR-200bc NAT2 .85 .016
hsa-miR-107 NAT1 .86 .024
hsa-miR-660 SULT1A2 .82 .034
hsa-miR-638 GSTA1 .82 .034
hsa-miR-638 UGT2B15 .82 .034
hsa-miR-25 GSTZ1 .82 .034
hsa-miR-18a UGT2B15 .82 .034
hsa-miR-23ac UGT2B10b .82 .034
hsa-miR-744 UGT2A3 .82 .034
hsa-miR-766 GSTA1 .79 .048
hsa-miR-766 UGT2B15 .79 .048








hsa-miR-31 GSTO1 .79 .048
hsa-miR-200bc SULT1A2 .76 .049
aSpearman correlation as assumption of normal distribution could not be
made. Only significant correlations reported (P < .05 by Spearman corre-
lation). Only those genes and miRNAs significantly altered by rifampin
treatment (up- or down-regulated >1.25-fold and P < .05) were included
in the correlation analyses.
bDenotes genes predicted via TargetScan to be targets of the correlated
miRNA.
cCorrespond to the nonpredominantly expressed miRNA sequence.
TPMT, thiopurine S-methyltransferase.
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Several miRNAs have been suggested to modulate conjugating
enzyme expression and function. miR-376c was identified as a mod-
ulator of UGT2B15 and UGT2B17 in prostate cancer cell lines.10
This observation was later confirmed and expanded to include miR-
331-5p, miR-376c-3p (formerly miR-368-1) for UGT2B15 and miR-
376c, miR-409, and miR-494 for UGT2B17.9 miR-216b has been
identified in silico as a potential modulator of several UGT2B family
members, including UGT2B15.7 Similarly, miR-491-3p is associated
with UGT1A1 expression and activity changes in hepatic cell lines8
However, the expected inverse correlation between the levels of
miR-491-3p and UGT1A1 mRNA were not demonstrated in a panel
of 38 normal livers. More recently, a functional genomics approach
assessed the complete compliment of miRNAs that could regulate
UGT1A expression and identified 6 additional miRNAs (miR-21-3p,
miR-200a-3p, miR-103b, miR-1286, miR-376b-3p, and miR-141-3p)
that decrease UGT1A-dependent activity.13 SULT1A1 expression in
human liver has been associated with miR-631 expression levels.56
miR-133a has been associated with repression of GSTP1 mRNA and
protein in lung and bladder cancer cell lines57,58 while miR-133b has
been associated with repressed GSTP1 mRNA expression in prostate
cancer cell lines.59 miR-513a-3p has also been associated with
repressed GSTP1 expression in lung cancer cells.60 An inverse corre-
lation between PXR translational efficiency and miR-148a has also
been reported.61 Interestingly, none of these miRNAs were revealed
by our correlation analysis. This may be the result of both direct and
indirect mechanisms mediated via rifampin induction. However, the
miRNA-mRNA pairs identified in Table 4, particularly those predicted
via TargetScan, may represent a reasonable starting point to better
understand the interplay of miRNA modulation and transcription fac-
tor activation via functional and mechanistic studies.
Induction of UGT1A4 observed in vitro prompted evaluation
via PBPK modeling and simulation. An available dataset which
included the UGT1A4 mediated N-glucuronide metabolite of mida-
zolam was utilized to evaluate the potential contribution of iso-
lated and simultaneous CYP450 and UGT1A4 induction. It is
acknowledged that induction of midazolam N-glucuronidation is
unlikely to be of clinical significance owing to the relatively minor
contribution of UGT1A4 to overall midazolam clearance. However,
this exemplar drug–drug interaction highlights the potential impor-
tance of considering simultaneous induction of alternate pathways,
F IGURE 2 Physiologically based
pharmacokinetic model predicted effects of
rifampin-induced midazolam metabolism.
Observed and predicted midazolam (A) and
midazolam N-glucuronide (B)
concentration-time profiles following oral
administration of midazolam (5 mg) to
healthy volunteers (n = 12). Predicted
midazolam and N-glucuronide
concentration-time profiles considering the
effects of rifampin coadministration
(600 mg/day orally for 3 days) resulting in
the following: UGT1A4 induction only (C
and D), CYP3A induction only (E and F),
and simultaneous induction of both
UGT1A4 and CYP3A (G and H). Blue and
green lines correspond to midazolam and
N-glucuronide disposition when taken
alone or with rifampin, respectively. Solid
and dashed lines denote the predicted
arithmetic mean and 95% confidence
intervals, respectively. Dots denote
observed individual data; each color
represents data from a single healthy
volunteer (n = 12). PBPK, physiologically
based pharmacokinetic
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particularly for drugs where the fraction metabolized by CYP450
is relatively lower than that of midazolam. Including induction of
all known metabolic pathways into predictive PBPK drug–drug
interaction models may also help alleviate the systematic tendency
to under predict the magnitude of drug–drug interactions resulting
from induction.
These data reveal differential effects of rifampin on the human
conjugating enzyme transcriptome and potential associations with
miRNAs. The magnitude of phase 2 enzyme mRNA induction in
response to rifampin was relatively lower than that observed for
induction of CYP450 enzymes. This may be the result of a relatively
lesser contribution of PXR-mediated induction to the overall induction
potential of the conjugating enzymes evaluated. We acknowledge that
mRNA expression changes may not directly reflect changes in protein
content and activity. Further studies are needed to evaluate the corre-
lations between rifampin-induced mRNA expression changes, miRNA
modulation, and enzyme activity as posttranscriptional and posttrans-
lation modifications may alter this relationship. However, this global
expression approach was aimed at revealing additional factors that
might contribute to regulation of important drug metabolizing
enzymes. These findings should inform future studies to elucidate and
quantitatively predict the impact of epigenetic regulation and conju-
gating enzyme induction on clinical drug disposition.
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AUCobs 209 (160-274) AUCobs 54.7 (45.3-66.0)
AUCpred 185 (162-213) AUCpred 51.7 (44.9-59.7)
Cmaxobs 74.2 (56.5-97.5) Cmaxobs 4.17 (3.46-5.03)
Cmaxpred 50.0 (44.1-56.6) Cmaxpred 4.25 (3.73-4.84)
Rifampin UGT induction only
AUCind 165 (144-188) AUCind 219 (192-250)
1/AUCratio 1.12 (0.98-1.28) AUCratio 4.24 (3.22-5.57)
Cmaxind 46.7 (41.3-52.8) Cmaxind 18.5 (16.4-20.9)
1/Cmaxratio 1.07 (0.95-1.21) Cmaxratio 4.35 (3.39-5.62)
Rifampin CYP3A induction only
AUCind 19.1 (15.4-23.7) AUCind 5.43 (4.36-6.77)
1/AUCratio 9.72 (8.48-11.2) 1/AUCratio 9.52 (8.30-10.9)
Cmaxind 7.44 (6.01-9.22) Cmaxind 0.54 (0.43-0.66)
1/Cmaxratio 6.71 (5.87-7.67) 1/Cmaxratio 7.94 (9.08-6.93)
Rifampin CYP3A and UGT induction
AUCind 18.4 (14.9-22.8) AUCind 24.8 (20.0-30.78)
1/AUCratio 10.1 (9.32-11.1) 1/AUCratio 2.08 (2.24-1.94)
Cmaxind 7.23 (5.85-8.94) Cmaxind 2.48 (2.02-3.05)
1/Cmaxratio 6.91 (6.33-7.69) 1/Cmaxratio 1.71 (1.59-1.85)
Observed data recovered from a healthy volunteer (n = 12) study in which participants were adminis-
tered a single oral dose (5 mg) of midazolam. AUCobs, observed area under the plasma concentration-time
curve (nmol/L 9 hours); AUCpred, predicted area under the plasma concentration-time curve (nmol/
L 9 hours); AUCInd, predicted area under the plasma concentration-time curve following rifampin induc-
tion (nmol/L 9 hours); AUCratio, rifampin treatment:control ratio; Cmaxobs , maximal observed plasma con-
centration (nmol/L); Cmaxpred , maximal predicted concentration (nmol/L); Cmaxratio , rifampin
treatment:control ratio; Cmaxind , predicted maximal concentration following rifampin induction (nmol/L).
Values denote geometric mean and 95% confidence intervals.
TABLE 5 Model-predicted rifampin
mediated drug–drug interaction with
midazolam
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